Seno
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Seno - overview
Established
2024
Location
Shenzhen, Guangdong, China
Primary Industry
Consumer Products
About
Seno, based in Shenzhen, China, specializes in manufacturing nicotine oral films, providing a modern alternative to traditional nicotine consumption methods. The company leverages advanced biomedical technologies to enhance user experience and promote healthier lifestyle choices. Founded in 2024, Seno operates out of Shenzhen, China, focusing on innovative nicotine oral film solutions. In December 2025, the firm raised USD 700,000 in pre-seed funding from unspecified investors, marking the first major investment for the company.
No significant pivots or changes in strategy have been noted since its establishment. Seno specializes in the manufacturing of nicotine oral films, designed to offer a modern and healthier alternative to traditional nicotine consumption methods. Utilizing advanced biomedical technologies, these films cater to a diverse client base across North America and Europe, where the demand for innovative nicotine products is rising. The films provide a discreet approach to managing nicotine intake, appealing to current users seeking alternatives and individuals interested in harm-reduction solutions.
Seno generates revenue through direct sales of its nicotine oral films to consumers and retail partners. Its sales structure includes B2B relationships with wholesalers, allowing for broader market distribution. The flagship product line includes nicotine oral films available in various flavors and strengths to meet a wide audience's needs. This pricing strategy ensures accessibility and supports revenue growth through consistent product sales and solid partnerships in the health and wellness sectors.
In December 2025, Seno aims to utilize the USD 700,000 raised in pre-seed funding to enhance its research and development capabilities, focusing on testing and validation activities, as well as improving quality and safety systems. The company plans to expand its offerings by launching new flavors and strengths of its nicotine oral films, with a goal of entering additional markets in Asia and Europe by late 2026.
Primary Industry
Consumer Products
Sub Industries
Cigarettes, Cigars & E-cigarettes
Website
www.senonicotine.com/
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.